Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...

Northwestern University researchers have tested a method to reduce the dreaded nocturnal itch-scratch cycle. Using an ...

In this Q&A, Marty Becker, DVM, Elite FFCP-V and Paul Bloom, DVM, DACVD, DABVP (Canine and Feline), Elite FFCP-III share ...

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...

A 0.15% once-daily roflumilast cream improved symptoms of atopic dermatitis (AD) across multiple endpoints, according to ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

Biologic treatments are a new option for people with moderate to severe eczema or atopic dermatitis. Most people can control eczema with prevention techniques, topical treatments, or ultraviolet ...

The global atopic dermatitis treatment market is on the cusp of remarkable expansion, with projections indicating a surge in ...

Diagnosing atopic dermatitis is a matter of just ruling out all other causes of itching, which can be somewhat difficult at times. But one of the big things that we typically start to rule out is ...